REAN Foundation

    • Register
    • Login
    • Search
    • Categories
    • Unread
    • Recent
    • Tags
    • Popular
    • Admin

    HIV-Associated Lipodystrophy

    General Health
    2
    2
    24
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • X
      Xander last edited by

      What is HIV-Associated Lipodystrophy and how is it managed?

      A 1 Reply Last reply Reply Quote 0
      • A
        Adrieyl @Xander last edited by

        @xander HIV lipodystrophy is a syndrome of abnormal central fat accumulation and/or localized loss of fat tissue that occurs in patients taking antiretroviral drugs. Tesamorelin (Egrifta), a growth hormone–releasing factor, was approved by the US Food and Drug Administration in 2010 to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy.
        FDA approval of tesamorelin was based on 2 studies in which visceral adipose tissue was significantly decreased from baseline at 26 weeks and sustained at 52 weeks. These multicenter, randomized, double-blind, placebo-controlled phase 3 studies consisting of a 26-week main phase and a 26-week extension phase in 816 HIV-infected patients with excess abdominal fat associated with lipodystrophy. In phase III, randomized, double-blind studies that assessed the effect of tesamorelin on HIV-associated abdominal fat accumulation, a reduction in adiposity correlated with overall improved metabolic profiles of lipids and glucose.

        1 Reply Last reply Reply Quote 0
        • First post
          Last post